Moloney Securities Asset Management LLC Sells 83,500 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Moloney Securities Asset Management LLC reduced its stake in SOPHiA GENETICS SA (NASDAQ:SOPH) by 50.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 81,500 shares of the company’s stock after selling 83,500 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in SOPHiA GENETICS were worth $297,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Green Alpha Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter worth $79,000. Federated Hermes Inc. lifted its stake in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares during the last quarter. Banque Cantonale Vaudoise lifted its stake in SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after purchasing an additional 9,000 shares during the last quarter. Principal Financial Group Inc. lifted its stake in SOPHiA GENETICS by 35.9% during the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after purchasing an additional 361,201 shares during the last quarter. Finally, Akre Capital Management LLC bought a new stake in SOPHiA GENETICS during the first quarter worth $1,418,000. 31.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on SOPH. Royal Bank of Canada cut their target price on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Morgan Stanley downgraded shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $10.00 to $5.00 in a report on Wednesday, August 7th.

SOPHiA GENETICS Stock Down 9.3 %

Shares of NASDAQ:SOPH opened at $3.40 on Thursday. The company has a fifty day moving average of $3.68 and a 200-day moving average of $4.24. The company has a market capitalization of $222.29 million, a PE ratio of -3.28 and a beta of 1.03. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.17 and a current ratio of 4.40. SOPHiA GENETICS SA has a 52-week low of $2.70 and a 52-week high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.05. The company had revenue of $15.81 million during the quarter, compared to the consensus estimate of $17.58 million. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. During the same period in the prior year, the business earned ($0.33) earnings per share. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.95 EPS for the current fiscal year.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.